NCT01412944

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

A Randomized, Double-blind, Double Dummy, Multicenter Study to Assess the Safety, Tolerability and Long-term Efficacy of Intravenous (10mg/kg) and Subcutaneous (300mg) Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Who Are Partial Responders to Secukinumab

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous (300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial responders to secukinumab.

Conditions

• Plaque-type Psoriasis

Interventions

Type	Name	Description
DRUG	secukinumab 150mg	secukinumab 150mg (2 injections per dose)
DRUG	secukinumab 10mg/kg i.v. regimen	secukinumab 10mg/kg i.v. regimen

Timeline

• Start date: 2011-12-01
• Primary completion: 2013-04-01
• Completion: 2013-04-01
• First posted: 2011-08-09
• Last updated: 2015-03-18
• Results posted: 2015-03-18

Locations

27 sites across 8 countries: United States, Austria, Canada, France, Germany, India, Japan, Slovakia